Welcome to our dedicated page for ROCKET PHARMACEUTICALS SEC filings (Ticker: RCKTW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ROCKET PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ROCKET PHARMACEUTICALS's regulatory disclosures and financial reporting.
ROCKET PHARMACEUTICALS, INC. General Counsel Martin Wilson reported an open-market sale of 3,361 shares of common stock at $3.606 per share. The footnotes state the shares were sold to cover tax withholding obligations arising from the vesting of Restricted Stock Units that convert to common stock on a one-for-one basis. After this transaction, Wilson directly holds 678,639 shares, so the sale represents only a small portion of his overall position and appears tied to compensation-related taxes rather than a discretionary portfolio change.
ROCKET PHARMACEUTICALS, INC. General Counsel Martin Wilson reported an open-market sale of 3,361 shares of common stock at $3.606 per share. The footnotes state the shares were sold to cover tax withholding obligations arising from the vesting of Restricted Stock Units that convert to common stock on a one-for-one basis. After this transaction, Wilson directly holds 678,639 shares, so the sale represents only a small portion of his overall position and appears tied to compensation-related taxes rather than a discretionary portfolio change.
ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah reported a small sale of common stock mainly tied to taxes on equity compensation. He sold 2,728 shares on May 13, 2026 at $3.606 per share to pay tax withholding obligations related to vesting restricted stock units.
After this sale, he directly holds 1,043,327 shares of common stock, with additional indirect holdings of 198,341 shares through the Gaurav D. Shah Irrevocable Trust and 207,897 shares held by his spouse. Footnotes note that these holdings include RSUs that convert one-for-one into common stock.
ROCKET PHARMACEUTICALS, INC. CEO Gaurav Shah reported a small sale of common stock mainly tied to taxes on equity compensation. He sold 2,728 shares on May 13, 2026 at $3.606 per share to pay tax withholding obligations related to vesting restricted stock units.
After this sale, he directly holds 1,043,327 shares of common stock, with additional indirect holdings of 198,341 shares through the Gaurav D. Shah Irrevocable Trust and 207,897 shares held by his spouse. Footnotes note that these holdings include RSUs that convert one-for-one into common stock.
ROCKET PHARMACEUTICALS, INC. officer John Militello reported an open-market sale of common stock tied to equity compensation. He sold 855 shares at $3.606 per share, with the transaction occurring to cover tax withholding obligations from the vesting of Restricted Stock Units that convert to common stock on a one-for-one basis.
After this sale, Militello directly holds 90,164 shares of common stock, including RSUs. The transaction represents a small portion of his overall reported holdings and is characterized in the footnotes as a tax-related disposition rather than a discretionary share sale.
ROCKET PHARMACEUTICALS, INC. officer John Militello reported an open-market sale of common stock tied to equity compensation. He sold 855 shares at $3.606 per share, with the transaction occurring to cover tax withholding obligations from the vesting of Restricted Stock Units that convert to common stock on a one-for-one basis.
After this sale, Militello directly holds 90,164 shares of common stock, including RSUs. The transaction represents a small portion of his overall reported holdings and is characterized in the footnotes as a tax-related disposition rather than a discretionary share sale.
RCKT submitted a Rule 144 notice disclosing 3,361 shares of Common Stock tied to a restricted stock vesting event dated 05/11/2026.
The filing also lists prior sales by Martin Wilson of 12,253 shares on 02/13/2026 for $40,583.16 and 1,376 shares on 02/18/2026 for $4,593.78.
RCKT submitted a Rule 144 notice disclosing 3,361 shares of Common Stock tied to a restricted stock vesting event dated 05/11/2026.
The filing also lists prior sales by Martin Wilson of 12,253 shares on 02/13/2026 for $40,583.16 and 1,376 shares on 02/18/2026 for $4,593.78.
Rocket Pharmaceuticals (RCKT) filed a Form 144 reporting proposed sales tied to recent restricted stock vesting. The filing lists 2,728 shares in a restricted stock vesting entry dated 05/11/2026 and two past reported dispositions by Gaurav Shah of 12,279 and 5,990 shares on 02/13/2026 and 02/18/2026, with associated dollar figures shown in the excerpt.
Rocket Pharmaceuticals (RCKT) filed a Form 144 reporting proposed sales tied to recent restricted stock vesting. The filing lists 2,728 shares in a restricted stock vesting entry dated 05/11/2026 and two past reported dispositions by Gaurav Shah of 12,279 and 5,990 shares on 02/13/2026 and 02/18/2026, with associated dollar figures shown in the excerpt.
RCKT submitted a Form 144 reporting 855 shares of Common Stock to be sold in connection with Restricted Stock Vesting on 05/11/2026.
The filing also records prior sales: 3,726 shares on 02/13/2026 for $12,340.88 and 1,157 shares on 02/18/2026 for $3,862.64.
RCKT submitted a Form 144 reporting 855 shares of Common Stock to be sold in connection with Restricted Stock Vesting on 05/11/2026.
The filing also records prior sales: 3,726 shares on 02/13/2026 for $12,340.88 and 1,157 shares on 02/18/2026 for $3,862.64.
ROCKET PHARMACEUTALS, INC. insider Sarbani Chaudhuri reported an open-market sale of 17,650 shares of common stock at $3.838 per share on May 7, 2026. According to the disclosure, the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs). After this transaction, Chaudhuri holds 267,510 shares of common stock, which includes RSUs that convert into common stock on a one-for-one basis.
ROCKET PHARMACEUTALS, INC. insider Sarbani Chaudhuri reported an open-market sale of 17,650 shares of common stock at $3.838 per share on May 7, 2026. According to the disclosure, the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units (RSUs). After this transaction, Chaudhuri holds 267,510 shares of common stock, which includes RSUs that convert into common stock on a one-for-one basis.
Rocket Pharmaceuticals, Inc. reported first quarter 2026 results and highlighted major pipeline and financing milestones. The company received FDA accelerated approval for KRESLADI for severe LAD-I and monetized a Rare Pediatric Disease Priority Review Voucher for $180 million.
Pro forma cash, cash equivalents and investments were approximately $322.6 million, providing an expected operational runway into the second quarter of 2028. For the three months ended March 31, 2026, Rocket recorded a net loss of $47.6 million compared with $61.3 million a year earlier, with total operating expenses declining to $48.5 million from $64.4 million. Cash, cash equivalents and investments were $144.4 million as of March 31, 2026.
Rocket Pharmaceuticals, Inc. reported first quarter 2026 results and highlighted major pipeline and financing milestones. The company received FDA accelerated approval for KRESLADI for severe LAD-I and monetized a Rare Pediatric Disease Priority Review Voucher for $180 million.
Pro forma cash, cash equivalents and investments were approximately $322.6 million, providing an expected operational runway into the second quarter of 2028. For the three months ended March 31, 2026, Rocket recorded a net loss of $47.6 million compared with $61.3 million a year earlier, with total operating expenses declining to $48.5 million from $64.4 million. Cash, cash equivalents and investments were $144.4 million as of March 31, 2026.
Rocket Pharmaceuticals reported another quarterly loss as it transitions to commercial stage. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $47.6 million versus $61.3 million a year earlier, as both research and development and general and administrative expenses declined.
Cash, cash equivalents and investments totaled $144.4 million as of March 31, 2026. In March, the FDA granted accelerated approval for KRESLADI™ for severe LAD‑I, and in April the company signed a definitive agreement to sell the related Priority Review Voucher for $180 million, which management expects will provide non‑dilutive funding to support its cardiovascular gene therapy pipeline and extend its operating runway by at least twelve months. Rocket also continues to face class action and derivative litigation tied to disclosures about its Danon disease program.
Rocket Pharmaceuticals reported another quarterly loss as it transitions to commercial stage. For the three months ended March 31, 2026, the company generated no revenue and recorded a net loss of $47.6 million versus $61.3 million a year earlier, as both research and development and general and administrative expenses declined.
Cash, cash equivalents and investments totaled $144.4 million as of March 31, 2026. In March, the FDA granted accelerated approval for KRESLADI™ for severe LAD‑I, and in April the company signed a definitive agreement to sell the related Priority Review Voucher for $180 million, which management expects will provide non‑dilutive funding to support its cardiovascular gene therapy pipeline and extend its operating runway by at least twelve months. Rocket also continues to face class action and derivative litigation tied to disclosures about its Danon disease program.